INmune Bio (INMB) Stock Forecast, Price Target & Predictions
INMB Stock Forecast
INmune Bio stock forecast is as follows: an average price target of $22.00 (represents a 252.00% upside from INMB’s last price of $6.25) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
INMB Price Target
The average price target for INmune Bio (INMB) is $22.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $22.00. This represents a potential 252.00% upside from INMB's last price of $6.25.
INMB Analyst Ratings
According to 2 Wall Street analysts, INmune Bio's rating consensus is 'Buy'. The analyst rating breakdown for INMB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
INmune Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 22, 2024 | George Farmer | Scotiabank | $22.00 | $6.85 | 221.17% | 252.00% |
The latest INmune Bio stock forecast, released on Aug 22, 2024 by George Farmer from Scotiabank, set a price target of $22.00, which represents a 221.17% increase from the stock price at the time of the forecast ($6.85), and a 252.00% increase from INMB last price ($6.25).
INmune Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $22.00 | $22.00 |
| Last Closing Price | $6.25 | $6.25 | $6.25 |
| Upside/Downside | -100.00% | 252.00% | 252.00% |
In the current month, the average price target of INmune Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to INmune Bio's last price of $6.25. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 26, 2024 | Raymond James | - | Outperform | Initialise |
| Sep 18, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Sep 18, 2024 | BTIG | Buy | Buy | Hold |
| Aug 21, 2024 | Scotiabank | - | Outperform | Initialise |
INmune Bio's last stock rating was published by Raymond James on Sep 26, 2024. The company Initialise its INMB rating from "null" to "Outperform".
INmune Bio Financial Forecast
INmune Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $-282.00K | $43.00K | $46.00K | $163.00K | $14.00K | $4.00K | - |
| Avg Forecast | - | - | - | - | $-3.33K | $333.00 | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $226.67K | $1.45M | $3.26K | $83.50K |
| High Forecast | - | - | - | - | $-3.33K | $333.00 | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $272.00K | $1.45M | $3.91K | $83.50K |
| Low Forecast | - | - | - | - | $-3.33K | $333.00 | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $181.34K | $1.45M | $2.61K | $83.50K |
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | -6.56% | 0.93% | 1.21% | 0.72% | 0.01% | 1.23% | - |
INmune Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $28.00K, with a low forecast of $28.00K, and a high forecast of $28.00K. INMB's average Quarter revenue forecast represents a -109.93% decrease compared to the company's last Quarter revenue of $-282.00K (Dec 23).
INmune Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $45.07M | $-8.53M | $-6.41M | $-6.48M | $-9.46M | $-4.56M | $-1.90M |
| Avg Forecast | - | - | - | - | $2.76K | $-275.00 | $-11.59K | $-23.18K | $-35.60K | $-38.08K | $-31.46K | $-9.60M | $-1.20M | $-3.71M | $-1.81M |
| High Forecast | - | - | - | - | $2.76K | $-275.00 | $-11.59K | $-23.18K | $-35.60K | $-38.08K | $-31.46K | $-7.68M | $-1.20M | $-2.97M | $-1.45M |
| Low Forecast | - | - | - | - | $2.76K | $-275.00 | $-11.59K | $-23.18K | $-35.60K | $-38.08K | $-31.46K | $-11.52M | $-1.20M | $-4.45M | $-2.17M |
| Surprise % | - | - | - | - | - | - | - | - | -1266.10% | 223.93% | 203.78% | 0.67% | 7.88% | 1.23% | 1.05% |
1 analysts predict INMB's average Quarter EBITDA for Mar 24 to be $-23.18K, with a high of $-23.18K and a low of $-23.18K. This is -100.05% lower than INmune Bio's previous annual EBITDA (Dec 23) of $45.07M.
INmune Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $51.72M | $-8.56M | $-6.50M | $-7.33M | $-9.46M | $-4.56M | $-1.90M |
| Avg Forecast | $-8.38M | $-7.87M | $-8.28M | $-9.49M | $-11.36M | $-10.23M | $-12.72M | $-10.80M | $-8.61M | $-7.94M | $-8.00M | $-9.60M | $-7.00M | $-3.71M | $-1.80M |
| High Forecast | $-8.38M | $-7.87M | $-8.28M | $-9.49M | $-11.36M | $-10.23M | $-12.72M | $-10.80M | $-6.85M | $-7.94M | $-8.00M | $-7.68M | $-7.00M | $-2.97M | $-1.44M |
| Low Forecast | $-8.38M | $-7.87M | $-8.28M | $-9.49M | $-11.36M | $-10.23M | $-12.72M | $-10.80M | $-10.37M | $-7.94M | $-8.00M | $-11.52M | $-7.00M | $-4.45M | $-2.16M |
| Surprise % | - | - | - | - | - | - | - | - | -6.01% | 1.08% | 0.81% | 0.76% | 1.35% | 1.23% | 1.06% |
INmune Bio's average Quarter net income forecast for Mar 24 is $-10.80M, with a range of $-10.80M to $-10.80M. INMB's average Quarter net income forecast represents a -120.88% decrease compared to the company's last Quarter net income of $51.72M (Dec 23).
INmune Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $2.40M | $2.59M | $2.31M | $2.33M | $2.52M | $2.06M | $1.81M |
| Avg Forecast | - | - | - | - | $-476.32K | $47.59K | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $32.39M | $207.22M | $465.74K | $11.93M |
| High Forecast | - | - | - | - | $-476.32K | $47.59K | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $38.87M | $207.22M | $558.64K | $11.93M |
| Low Forecast | - | - | - | - | $-476.32K | $47.59K | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $25.91M | $207.22M | $372.57K | $11.93M |
| Surprise % | - | - | - | - | - | - | - | - | 0.39% | 0.39% | 0.43% | 0.07% | 0.01% | 4.43% | 0.15% |
INmune Bio's average Quarter SG&A projection for Mar 24 is $4.00M, based on 1 Wall Street analysts, with a range of $4.00M to $4.00M. The forecast indicates a 66.73% rise compared to INMB last annual SG&A of $2.40M (Dec 23).
INmune Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 17 | 8 | 10 | 8 |
| EPS | - | - | - | - | - | - | - | - | $1.21 | $-0.00 | $-0.00 | $-0.41 | $-0.55 | $-0.32 | $-0.20 |
| Avg Forecast | $-0.41 | $-0.39 | $-0.41 | $-0.47 | $-0.56 | $-0.51 | $-0.63 | $-0.54 | $-0.43 | $-0.39 | $-0.40 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
| High Forecast | $-0.41 | $-0.39 | $-0.41 | $-0.47 | $-0.56 | $-0.51 | $-0.63 | $-0.54 | $-0.34 | $-0.39 | $-0.40 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
| Low Forecast | $-0.41 | $-0.39 | $-0.41 | $-0.47 | $-0.56 | $-0.51 | $-0.63 | $-0.54 | $-0.51 | $-0.39 | $-0.40 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
| Surprise % | - | - | - | - | - | - | - | - | -2.84% | 0.00% | 0.00% | 0.72% | 1.52% | 1.17% | 1.05% |
According to 1 Wall Street analysts, INmune Bio's projected average Quarter EPS for Mar 24 is $-0.54, with a low estimate of $-0.54 and a high estimate of $-0.54. This represents a -144.21% decrease compared to INMB previous annual EPS of $1.21 (Dec 23).
INmune Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.30 | $14.00 | 4566.67% | Buy |
| ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
| PYPD | PolyPid | $3.33 | $25.00 | 650.75% | Buy |
| DRMA | Dermata Therapeutics | $1.22 | $6.00 | 391.80% | Buy |
| AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
| INMB | INmune Bio | $6.25 | $22.00 | 252.00% | Buy |
| CUE | Cue Biopharma | $1.49 | $5.00 | 235.57% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| TCRX | TScan Therapeutics | $5.08 | $12.00 | 136.22% | Buy |
| ANIX | Anixa Biosciences | $3.45 | $7.50 | 117.39% | Buy |
| AVXL | Anavex Life Sciences | $7.30 | $11.00 | 50.68% | Buy |
INMB Forecast FAQ
Is INmune Bio a good buy?
Yes, according to 2 Wall Street analysts, INmune Bio (INMB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of INMB's total ratings.
What is INMB's price target?
INmune Bio (INMB) average price target is $22 with a range of $22 to $22, implying a 252.00% from its last price of $6.25. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will INmune Bio stock go up soon?
According to Wall Street analysts' prediction for INMB stock, the company can go up by 252.00% (from the last price of $6.25 to the average price target of $22), up by 252.00% based on the highest stock price target, and up by 252.00% based on the lowest stock price target.
Can INmune Bio stock reach $9?
INMB's average twelve months analyst stock price target of $22 supports the claim that INmune Bio can reach $9 in the near future.
What are INmune Bio's analysts' financial forecasts?
INmune Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $39K (high $39K, low $39K), average EBITDA is $-32.287K (high $-32.287K, low $-32.287K), average net income is $-45.105M (high $-45.105M, low $-45.105M), average SG&A $5.57M (high $5.57M, low $5.57M), and average EPS is $-2.235 (high $-2.235, low $-2.235). INMB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.013M (high $-34.013M, low $-34.013M), average SG&A $0 (high $0, low $0), and average EPS is $-1.685 (high $-1.685, low $-1.685).
Did the INMB's actual financial results beat the analysts' financial forecasts?
Based on INmune Bio's last annual report (Dec 2023), the company's revenue was $-155K, which missed the average analysts forecast of $127K by -222.05%. Apple's EBITDA was $30.01M, missing the average prediction of $-105K by -28640.45%. The company's net income was $30.01M, missing the average estimation of $-24.555M by -222.21%. Apple's SG&A was $9.62M, missing the average forecast of $18.15M by -46.98%. Lastly, the company's EPS was $0, missing the average prediction of $-1.216 by -100.00%. In terms of the last quarterly report (Dec 2023), INmune Bio's revenue was $-282K, missing the average analysts' forecast of $43K by -755.81%. The company's EBITDA was $45.07M, missing the average prediction of $-35.599K by -126710.30%. INmune Bio's net income was $51.72M, missing the average estimation of $-8.613M by -700.53%. The company's SG&A was $2.4M, missing the average forecast of $6.15M by -60.94%. Lastly, the company's EPS was $1.21, missing the average prediction of $-0.427 by -383.59%